ABSTRACT
CS–12, which is a pseudonym for a Czech firm that wishes to remain anonymous, is the major Czech producer of pharmaceutical products. The Czech pharmaceutical industry is controlled by a number of government regulations and laws. The competitive structure of the Czech market may change significantly in the near future due to the privatization process in the sector. CS–12 faced a number of challenges in the course of the Czech economy’s transition. The number and structure of domestic customers changed significantly. CS–12’s management, with the assistance of advisers, prepared and started to implement a program of systematic changes in the company. The privatization of CS–12 was implemented by the National Property Fund according to the approved privatization project. The management of the company has major responsibilities and power within the limits approved in the privatization project. CS– 12 became slimmer in terms of size and sales but stronger in terms of economic performance.
